Other commenters have noted that the sensitivity is 100% with specificity 82% (false positive rate being 18%). I wanted to provide my own take on what that means for me as a future provider (I'm considering becoming a neurologist after medical school). I'm assuming to the data science crowd here, it's almost second nature to know what these numbers really mean in practice, but maybe I can provide some outside perspective.
When considering screening tests in medicine, we have to always balance the benefits and risks of conducting these tests on patients. We have to figure out how reliable a test is, and how patients benefit from earlier detection.
In this case, it's an imaging test, so noninvasive. However, it's a test that requires radiation (positron emission tomography or PET). So we already have to determine if that extra radiation dose is worth the increased risk for something like cancer. In an elderly population, it's almost certainly worth the scan given the radiation would not significantly impact their decades of accrued radiation damage.
Now, what happens if a patient has a positive test, 6 years earlier than they would normally? Let's assume for a moment that it was a true positive test. They could receive treatment earlier, which could improve their quality of life. They could adjust their risk factors to slow down the progression of disease. The treatment could have side effects, such as increased blood pressure. If we apply that to a large population scale, would we increase mortality associated with heart disease by treating patients with suspected Alzheimer's earlier?
Lastly, I wanted to touch on the effects of a screening test with a large amount of false positives. I would argue that a screening test should be allowed to have lots of false positives, simply because we can always do other tests (neuropsychiatric evaluation like MOCA score) to improve our accuracy of detection. However, if we do these other tests, we have to again balance the harms with the risks. Mammograms, for instance, could give false positives that could warrant a breast biopsy. In the case of Alzheimer's, a false positive could lead to stress and depression in an elderly population already at higher risk for stress related disease.
In short, screening tests are great if there's a way to do something about the disease. As far as I know, early prophylactic treatment (with current medications) of Alzheimer's does improve quality of life, slowing progression of the disease manifestations, with relatively few side effects.